Region Blekinge

Region Blekinge is conducting studies that aim to improve treatment outcomes for serious bacterial infections, focusing on optimal antibiotic choice and safe oral step‑down regimens.

• Comparison of penicillin‑susceptible Staphylococcus aureus bacteraemia treatments with benzylpenicillin versus cloxacillin
• Evaluation of oral pivmecillinam as a step‑down therapy for febrile Escherichia coli urinary tract infection
• Assessment of antimicrobial stewardship strategies to reduce resistance and improve patient safety

The site, located in Karlskrona, Sweden, contributes to a portfolio of 10 clinical trials led by 11 investigators, highlighting its commitment to advancing infectious disease care.

At Region Blekinge, investigators are evaluating innovative therapies to lower major cardiac events and enhance recovery after heart attacks and surgeries.

• Dual antiplatelet therapy with ticagrelor plus aspirin versus aspirin alone after isolated coronary artery bypass grafting
• Addition of evolocumab to standard lipid management in patients hospitalized for acute myocardial infarction
• Comparison of apixaban versus warfarin for left ventricular thrombus resolution post‑MI
• Initiation of spironolactone or eplerenone to reduce heart‑failure hospitalizations in patients with preserved ejection fraction

These cardiovascular trials reflect a broad effort to improve survival and quality of life for individuals with acute coronary syndrome, dyslipidemia, and heart‑failure conditions.

Research at the Karlskrona hospital includes population‑level interventions to prevent cervical disease and studies on the safety of labour induction outside the hospital setting.

• Combined HPV vaccination and screening program targeting women aged 23‑25 to accelerate elimination of HPV infection and cervical cancer
• Outpatient induction of labour compared with inpatient induction to assess safety and effectiveness

By integrating public‑health strategies with clinical evaluation, the site supports both preventive care and obstetric innovation.

The centre is testing an adjuvant approach to reduce cancer recurrence in patients with genetically defined colorectal tumors.

• Low‑dose aspirin therapy for stage II‑III colorectal cancer with somatic alterations in the PI3K pathway

This trial seeks to determine whether a simple, inexpensive medication can improve long‑term outcomes for individuals with high‑risk colon and rectal cancer.

A pediatric study is exploring whether early corticosteroid treatment can accelerate nerve recovery in children with acute facial paralysis.

• Cortisone versus placebo for acute facial nerve palsy (Bell’s palsy) in children, measured by the House‑Brackmann scale

The investigation aims to provide evidence for a therapy that could shorten disability and improve facial function after sudden nerve injury.

Metabolic research focuses on lipid disorders, evaluating whether intensified therapy can further lower the risk of recurrent cardiovascular events.

• Evolocumab combined with routine lipid management to reduce myocardial infarction, stroke, and cardiovascular death after acute MI
• Management of dyslipidemia as part of comprehensive secondary‑prevention strategies

These studies reflect the site’s dedication to addressing metabolic risk factors that contribute to heart disease and overall mortality.